权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Correlation between the erbB family gene mutation and clinico-pathological factors, in lung cancer.

肺癌中erbB家族基因突变与临床病理因素的相关性。

基本信息

批准号：
18390381
负责人：
SASAKI Hidefumi
金额：
$ 7.78万
依托单位：
Nagoya City University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2006
资助国家：
日本
起止时间：
2006 至 2007
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18390381/
关键词：
EGFR Molecular Target Gefitinib Lung Cancer ErbB3 ErbB4 ゲフィチニブ erbB2

项目摘要

Epidermal growth factor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib were approver for treatment of lung cancers. In 2004, we collaborated with Dana Farber Cancer Institute and found the EGFR somatic mutations at kinase domain from lung cance samples. The mutations were correlated with gefitinib sensitivity in vitro and in vivo. We have established the sensitive genotyping assays (Taq-Man; Lung cancer : 2005: 50: 375-384 and LightCycler; Cl in Cancer Res: 2005: 11: 2924-2929) to detect these EGFR mutations from clinical samples. Using these assays, we have evaluated the mutation status and clinico-pathological background. We have also evaluated the EGFR mutations at exon 20, as known as resistant mutant for gefitinib therapy. We have also performed the FISH analysis to examine the EGFR amplification status. ErbB3 and erbB4 expression and mutation were also examined, however, we did not find and erbB3 or erbB4 mutation. We have cont inued the collaboration with Dana Farber Cancer Institute and using the SNP array, we examined the gene mutation statuses for large scale lung cancer samples. The results were published at Nature Genetics (2007: 39: 347-351)

表皮生长因子（EGFR）酪氨酸激酶抑制剂吉非替尼和厄洛替尼被批准用于治疗肺癌。 2004年，我们与Dana Farber癌症研究所合作，从肺癌样本中发现了激酶结构域的EGFR体细胞突变。这些突变与体外和体内吉非替尼敏感性相关。我们已经建立了敏感的基因分型测定（Taq-Man；肺癌：2005：50：375-384和LightCycler；Cancer Res中的Cl：2005：11：2924-2929）来检测临床样本中的这些EGFR突变。使用这些测定，我们评估了突变状态和临床病理背景。我们还评估了外显子 20 的 EGFR 突变，即吉非替尼治疗的耐药突变体。我们还进行了 FISH 分析来检查 EGFR 扩增状态。还检查了 ErbB3 和 erbB4 的表达和突变，但是，我们没有发现 erbB3 或 erbB4 突变。我们继续与达纳法伯癌症研究所合作，利用SNP阵列检测大规模肺癌样本的基因突变状态。研究结果发表在 Nature Genetics (2007: 39: 347-351)

项目成果

期刊论文数量（0）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

EGFR exon 20 insertion mutation in Japanese lung cancer

DOI：
10.1016/j.lungcan.2007.06.024
发表时间：
2007-12-01
期刊：
LUNG CANCER
影响因子：
5.3
作者：
Sasaki, Hidefumi;Endo, Katsuhiko;Fujii, Yoshitaka
通讯作者：
Fujii, Yoshitaka

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

DOI：
10.1073/pnas.0510284103
发表时间：
2006-05-16
期刊：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
影响因子：
11.1
作者：
Ji, Hongbin;Zhao, Xiaojun;Wong, Kwok-Kin
通讯作者：
Wong, Kwok-Kin

ErbB4 expression and mutation in Japanese patients with lung cancer